Mouse models of glioblastoma for the evaluation of novel therapeutic strategies.
Mouse models of glioblastoma for the evaluation of novel therapeutic strategies.
复制标题
DOI：
10.1093/noajnl/vdab100
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Butowski NA
中科院分区：
文献类型：
--
作者：
Haddad AF;Young JS;Amara D;Berger MS;Raleigh DR;Aghi MK;Butowski NA
胶质母细胞瘤（GBM）是一种无法治愈的脑肿瘤，尽管采用了包括手术、化疗和电离辐射在内的积极标准治疗，但中位生存期约为15个月。小鼠模型促进了我们对GBM生物学的理解，并为GBM患者开发了新的治疗策略。然而，在测试发育疗法时，模型选择是至关重要的，每种GBM小鼠模型都有独特的优点和缺点，可能会影响实验结果的有效性和可翻译性。为了阐明这一过程，我们讨论了3种类型的小鼠GBM模型的优势和局限性：同基因模型，基因工程小鼠模型，异种移植模型，包括传统的异种移植细胞系和患者来源的异种移植模型。
Glioblastoma (GBM) is an incurable brain tumor with a median survival of approximately 15 months despite an aggressive standard of care that includes surgery, chemotherapy, and ionizing radiation. Mouse models have advanced our understanding of GBM biology and the development of novel therapeutic strategies for GBM patients. However, model selection is crucial when testing developmental therapeutics, and each mouse model of GBM has unique advantages and disadvantages that can influence the validity and translatability of experimental results. To shed light on this process, we discuss the strengths and limitations of 3 types of mouse GBM models in this review: syngeneic models, genetically engineered mouse models, and xenograft models, including traditional xenograft cell lines and patient-derived xenograft models.